Gastroenterology

Sponsored by Takeda Pharmaceuticals

Having reliable estimates can help governments and relevant agencies develop better test-and-treat strategies to reduce vertical transmission and total disease burden.

Subjective reader assessments performed best among several different parameters.

The treatment represents the first ever oral therapy approved by the FDA for lupus nephritis.

A related editorial noted the study authors’ numbers were higher than those of the Mayo Clinic.

About half of patients experienced adverse events, and two-thirds of those events were likely related to inflammatory bowel disease medications.

Researchers suggest bolstering beneficial gut species depleted in COVID-19 could mitigate severe disease.

It’s possible that C diff could be a marker for frailty in geriatric patients.

The negative effects of the pandemic may disrupt efforts to eradicate HBV as a public health threat by 2030.

Using piperacillin/tazobactam increases the risk for acute kidney injury, and this risk can be exacerbated by concurrent vancomycin.

New phase 3 data show the IL-23 inhibitor is associated with clinical remission and endoscopic response.

Anastomotic leak can increase morbidity, mortality, and length and cost of hospital stays.

There is not currently an FDA approved treatment for NASH.

Investigators compared the 2010 and 2017 IDSA and SHEA guidelines to identify which better predicted C diff patients’ severity and mortality.

The first approved generic product for injection glucagon is also indicated for diagnostic use, when appropriate.

Screening for hepatitis B virus has become the norm in patients about to undergo anti-tumor-necrosis factor α therapy, but new research finds the risk of reactivation of resolved infections is low.

The investigators called their findings the “opposite of what was expected.”

The study authors wrote that understanding this phenomena can lead to determining the best therapeutic strategy with DAAs for certain patients.

The investigators measured a 3.5-month period before and after a policy was implemented to preserve hospital resources.

The TARGET-NASH study seeks to shed light on treatment for NASH and NAFLD.

Experts offered their advice on 2 domains, topic identification and ranking of priorities, for pediatric research realms.